1. In Vivo

Biopharma Dealmaking Quarterly Statistics, Q4 2013

A look at financing, M&A, and alliance activity October–December 2013

Biopharma financing totaled $6.4 billion, a 39% increase over Q3. Twenty-three M&As were completed with a combined potential value of $19.8 billion, and there were 103 biopharma alliances totaling $2.5 billion in potential pre-commercialization value, down 25% from the previous quarter.

Biopharma financings in the last quarter of 2013 reached $6.4 billion, an increase of 39% over Q3’s $4.6 billion, thanks to a large boost from debt financings. The fourth quarter – the second-largest quarter of the year in terms of dollars raised – helped push 2013’s total to $26.6 billion, way above 2012’s $13.6 billion. (See Exhibit 1.) Almost half of 2013’s total came from Q2’s $11 billion take, which is largely attributed to Valeant Pharmaceuticals International Inc.’s concurrent $2.3 billion follow-on public offering [See Deal] and $3.2 billion sale of debt [See Deal] to fund its $8.7 billion acquisition of Bausch & Lomb Inc.[See Deal]

Exhibit 1

More from Deal-Making

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.